共 33 条
Oroxin A from Oroxylum indicum improves disordered lipid metabolism by inhibiting SREBPs in oleic acid-induced HepG2 cells and high-fat diet-fed non-insulin-resistant rats
被引:0
|作者:
Cai, Tianqi
[1
]
Xu, Xiaoxue
[1
]
Dong, Ling
[1
]
Liang, Shufei
[1
]
Xin, Meiling
[1
]
Wang, Tianqi
[2
]
Li, Tianxing
[3
]
Wang, Xudong
[4
]
Zheng, Weilong
[5
]
Wang, Chao
[1
]
Xu, Zhengbao
[1
]
Wang, Meng
[1
]
Song, Xinhua
[1
]
Li, Lingru
[3
]
Li, Jingda
[2
]
Sun, Wenlong
[1
,6
]
机构:
[1] Shandong Univ Technol, Sch Life Sci & Med, Zibo 255000, Shandong, Peoples R China
[2] Yangtze Univ, Coll Life Sci, Jingzhou 434000, Hubei, Peoples R China
[3] Beijing Univ Chinese Med, Natl Inst TCM Constitut & Prevent Med, Beijing 100000, Peoples R China
[4] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310000, Zhejiang, Peoples R China
[5] Taizhou Univ, Inst Biomass Resources, Taizhou 317700, Zhejiang, Peoples R China
[6] Shandong Univ Technol, Inst Biomed Res, Sch Life Sci, Zibo 255000, Shandong, Peoples R China
来源:
关键词:
Disordered lipid metabolism;
Hyperlipidaemia;
NAFLD;
Oroxin A;
SREBPs;
FLAVONOIDS;
STREPTOZOTOCIN;
DISEASE;
STRESS;
D O I:
10.1016/j.heliyon.2024.e29168
中图分类号:
O [数理科学和化学];
P [天文学、地球科学];
Q [生物科学];
N [自然科学总论];
学科分类号:
07 ;
0710 ;
09 ;
摘要:
Background: Lipid metabolism disorders have become a major global public health issue. Due to the complexity of these diseases, additional research and drugs are needed. Oroxin A, the major component of Oroxylum indicum (L.) Kurz (Bignoniaceae), can improve the lipid profiles of diabetic and insulin-resistant (IR) rats. Because insulin resistance is strongly correlated with lipid metabolism, improving insulin resistance may also constitute an effective strategy for improving lipid metabolism. Thus, additional research on the efficacy and mechanism of oroxin An under non-IR conditions is needed. Methods: In this study, we established lipid metabolism disorder model rats by high-fat diet feeding and fatty HepG2 cell lines by treatment with oleic acid and evaluated the therapeutic effect and mechanism of oroxin A in vitro and in vivo through biochemical indicator analysis, pathological staining, immunoblotting, and immunofluorescence staining. Results: Oroxin A improved disordered lipid metabolism under non-IR conditions, improved the plasma and hepatic lipid profiles, and enhanced the lipid-lowering action of atorvastatin. Additionally, oroxin A reduced the total triglyceride (TG) levels by inhibiting sterol regulatory element-binding protein 1 (SREBP1) expression and reducing the expression of acetyl coenzyme A carboxylase (ACC) and fatty acid synthase (FASN) in vivo and in vitro. Oroxin A also reduced the total cholesterol (TC) levels by inhibiting SREBP2 expression and reducing HMGCR expression in vivo and in vitro. In addition, oroxin A bound to low-density lipoprotein receptor (LDLR) and increased AMPK phosphorylation. Conclusions: Our results suggested that oroxin A may modulate the nuclear transcriptional activity of SREBPs by binding to LDLR proteins and increasing AMPK phosphorylation. Oroxin A may thus reduce lipid synthesis and could be used for the treatment and prevention of lipid metabolism disorders.
引用
收藏
页数:17
相关论文